Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Nutritional and Metabolic Diseases

Leiomyoma

Myofibroma

Disease Progression

Hyperinsulinism

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neoplasms, Connective Tissue

Connective Tissue Diseases

Donna D Baird, Ph.D.

The proposed study is designed to estimate the proportion of 35-49 year-old women in a large urban health plan who have had fibroids. The membership of the health plan is approximately 45% black, so estimates for black and white women can be compared. Risk factors for the condition will be studied, and uterine tissue from women having hysterectomies or myomectomies will be studied to identify genetic, hormonal, and protein mediators of tumor growth.

A randomly selected sample of about 1800 women age 35-49 who are members of the George Washington University Health Plan will be invited to participate. Presence of leiomyomas for premenopausal participants with no prior diagnosis of leiomyoma will be determined by an ultrasound examination. Presence of leiomyomas for premenopausal women who report a prior diagnosis of fibroids will be determined by ultrasound evidence in their medical record when available, and by self-report when not available. History of fibroids in postmenopausal women will be based on pathology records for those with surgical menopause and on radiology records or self-report for the small number of naturally postmenopausal women. Estimates of the proportion who have or have had fibroids will be compared for blacks and whites.

To examine risk factors for leiomyoma we will conduct a case-control analysis. Cases will be those women identified with leiomyoma from the random sample, supplemented by women in the same age range who have hysterectomies or myomectomies during the study period and hose excised uteri show evidence of fibroids on standard pathology examination. Women from the random sample with ultrasound or pathology evidence showing no uterine fibroids will constitute the control group. Controls will be compared to cases grouped by size of largest fibroid and grouped by clinical.

A telephone interview and self-administered questionnaire will provide information on demographic factors, medical history, dietary intake, reproductive history, life style factors, and occupational/environmental exposures. Blood will be collected from premenopausal women to measure lipids, insulin, and potential susceptibility genes. Urine will also be collected from premenopausal women early in their menstrual cycles to measure gonadotropin levels. Blood pressure, heart rate, weight, height, and waist-to-hip ration will be measured. Tissue from surgical specimens will be use by collaborators at NIEHS to measure cell proliferation and apoptosis, genetic factors, estrogen and progesterone receptor levels, protein markers of estrogen action, and growth factors.

Uterine leiomyomas are the leading cause of hysterectomy in the United States, accounting for over 200,000 procedures each year. Leiomyoma is a common condition with many tumors being asymptomatic. It is not known which women who have fibroids will develop clinical symptoms. In 1996-1999 the NIEHS Uterine Fibroid Study enrolled 1245 randomly selected premenopausal women, aged 35 to 49, who had been randomly selected from the membership roles of George Washington University Health Plan, a large prepaid health plan in Washington, D.C. Slightly over half of the participants were African American. Participants were asked about prior diagnoses of uterine leiomyomas, and 87% were examined by abdominal/transvaginal ultrasound to screen for uterine leiomyoma. Sixty-two percent of the 1245 had either had a prior diagnosis of leiomyoma or had sonogram evidence of the condition.

Study Objectives:

1. Monitor fibroid-related symptoms over time (Two follow-ups over a five-year period).
2. Measure the proportion of women who undergo major medical intervention (hysteroscopic resection, uterine artery embolization, laser coagulation, myomectomy, or hysterectomy).
3. Identify risk factors for increased symptom severity.
4. Identify risk factors for treatment intervention.

Methods: Premenopausal participants in the Uterine Fibroid Study (1996-1999) will be recontacted twice during the years 2001 - 2005 to obtain information about leiomyoma-related symptoms and medical or surgical treatments. Data will be collected with a computer-assisted telephone interview. Medical records of ultrasound or MRI examinations and major medical or surgical interventions will be abstracted to verify medical follow-up and treatment.

Significance: The presence of leiomyomas can be identified with ultrasound screening when the condition is asymptomatic. However, no data are available that allow clinicians to predict which women will experience morbidity. This longitudinal study will trace disease progression, and identify factors related to increased symptom severity and medical/surgical treatment. The findings could then be used to develop a systematic scoring system that can be used to identify women at high risk.

Risk Factors for Uterine Fibroids: A Case Control Study

Risk Factors for Uterine Fibroids: A Case Control Study and Follow-up Amendment to Study Disease Progression

National Institute of Environmental Health Sciences (NIEHS)

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Menorrhagia

Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.

The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.

Mirabilis High-Intensity Focused Ultrasound Treatment System

Michael Lau, M.D.

The Mirabilis High-Intensity Focused Ultrasound (HIFU) Treatment System delivers therapeutic focused ultrasound energy to the uterus under integrated ultrasound imaging guidance to offer non-invasive treatment for uterine fibroids. The purpose of this clinical study is to assess the initial safety and performance of the Mirabilis HIFU Treatment System for transabdominal treatment of uterine fibroids in eligible women who are scheduled to undergo hysterectomy following treatment with the device or who are seeking relief from fibroid-related symptoms.

Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids

Clinical Study of a Focused Ultrasound Device for Treating Uterine Fibroids and Menorrhagia

Safety of the treatment was determined by evaluating the incidence of Adverse Events and Adverse Device Effects. Adverse Device Effects are Adverse Events that are related to treatment with the device. Relatedness of an Adverse Event to the treatment was determined on a case-by-case basis by the investigator. The average number of Serious Adverse Device Effects per patient and the average number of Non-Serious Adverse Device Effects per patient are reported to provide numeric outcomes of this evaluation.

Efficacy of the treatment was quantified by measuring the HIFU-related Non-Perfused Volume (NPV) of tissue in each patient using either post-treatment contrast-enhanced magnetic resonance imaging (MRI) or pathology assessment following hysterectomy. The NPV is used to measure the amount of tissue that was treated during the procedure.

Mirabilis Medica, Inc.

All Adverse Events are reported for all patients receiving treatment, including those events not related to treatment. Adverse Events were reported spontaneously by patients, observed by the investigator or other personnel, and/or elicited during patient queries at regular follow-up intervals. Descriptions were mapped to standardized terms.

All patients who underwent treatment with the device

All Treated Patients

Age, Categorical

Age, Continuous

Sex: Female, Male

Mexico

Region of Enrollment

Baseline characteristics are reported for the entire study population (all treated patients).

Director of Clinical Affairs

Serious Adverse Device Effects Per Patient

Non-Serious Adverse Device Effects Per Patient

All Adverse Device Effects are reported for the entire study population (all treated patients).

Evaluation of All Adverse Events Encountered

The Development Cohort includes the first 37 patients treated in the study sequence. Treatments in the Development Cohort were used for dose-ranging purposes to develop the most appropriate HIFU parameters for uterine fibroid treatment with the device. Outcomes are reported for the 33 out of 37 patients (89.2%) in the Development Cohort with NPVs observed following treatment.

Overall, 68 out of 73 patients (93.2%) in the entire study had NPVs observed following treatment.

Development Cohort With NPVs Observed

The Validation Cohort includes the last 36 patients treated in the study sequence. Treatments in the Validation Cohort were used to refine and validate the final HIFU parameters for uterine fibroid treatment with the device. Outcomes are reported for the 35 out of 36 patients (97.2%) in the Validation Cohort with NPVs observed following treatment.

Overall, 68 out of 73 patients (93.2%) in the entire study had NPVs observed following treatment.

Validation Cohort With NPVs Observed

HIFU-related Non-Perfused Volumes (NPVs) are reported for all treated patients in whom they were observed following treatment. NPV outcomes are stratified between two cohorts: an early Development Cohort and a final Validation Cohort.

HIFU-related Non-Perfused Volume (NPV)

The total treatment time was measured for each patient from the beginning of HIFU energy emission until HIFU energy emission stopped.

The Development Cohort includes the first 37 patients treated in the study sequence. Treatments in the Development Cohort were used for dose-ranging purposes to develop the most appropriate HIFU parameters for uterine fibroid treatment with the device. Outcomes are reported for all 37 patients in the Development Cohort.

Entire Development Cohort

The Validation Cohort includes the last 36 patients treated in the study sequence. Treatments in the Validation Cohort were used to refine and validate the final HIFU parameters for uterine fibroid treatment with the device. Outcomes are reported for all 36 patients in the Validation Cohort.

Entire Validation Cohort

Total treatment times are reported for all treated patients. Total treatment times are stratified between two cohorts: an early Development Cohort and a final Validation Cohort.

Total Time Required to Deliver Treatment

Overall Study

Central Nervous System Depressants

All Drugs and Chemicals

Reproductive Control Agents

Anesthetics

Endothelial Growth Factors

Mitogens

Dinoprostone

22 patients receive general anesthesia and patient controlled intravenous analgesia

22 patients receive spinal anesthesia and continuous postoperative epidural analgesia

Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation

general anesthesia and patient controlled intravenous analgesia

Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation

spinal anesthesia and continuous postoperative epidural analgesia

The purpose of this study is to verify the effect of anesthetic technique on the change of postoperative serum vascular endothelial growth factor C and prostaglandin E2, and to explore the potential impact of the anesthetic technique on leiomyomas recurrence and growth after the surgery of abdominal myomectomy.

Uterine leiomyomas is the most common benign tumor of uterus, the most common tumor in women as well. Like many other forms of tumor, it requires an independent blood supply to enlarge. This process, angiogenesis, is mediated by vascular endothelial growth factor C (VEGF-C) and prostaglandin E2 (PGE2). Several studies have confirmed that VEGF-C has a high level in patients with uterine leiomyomas, which has also been demonstrated that it was related to occurrence and growth of uterine leiomyomas because it's capable of promoting angiogenesis, mitogenic, and vascular permeability-enhancing activities. Also, some researchers suggested that suppression of prostaglandin synthesis (including PGE2) via cyclooxygenase type-2 (COX-2) enzyme inhibition may reduce the incidence of some tumor. The aim of this study is to verify the effect of anesthetic technique on the change of postoperative serum VEGF-C and PGE2, and to explore the potential impact of the anesthetic technique on leiomyomas recurrence and growth after the surgery of abdominal myomectomy.

The Effect of Anesthetic Technique on VEGF-C and PGE2

Effect of Anesthetic Technique on Serum Vascular Endothelial Growth Factor C and Prostaglandin E2 in Women Undergoing Surgery for Uterine Leiomyomas

Blood samples were sampled before anesthesia and at 48h after surgery for the serum VEGF-C，which were analyzed by using enzyme linked immunosorbent assay (ELISA).

Blood samples were sampled before anesthesia and at 48h after surgery for the serum PGE2，which were analyzed by using enzyme linked immunosorbent assay (ELISA).

Visual analog scale (VAS) pain scores were used to evaluate postoperative pain at 2h, 4h, 8h, 12h, 24h and 48h after surgery by the anesthetist

General Hospital of Ningxia Medical University

Mifepristone

Contraceptive Agents

Contraceptives, Oral

Contraceptive Agents, Female

Contraceptives, Postcoital

Hormones

Hormone Antagonists

Contraceptive Agents, Hormonal

Mifepristone (Mifegyne) 50 mg every other day for 3 months

Mifegyne

placebo

Kristina Gemzell Danielsson, Prof.MD.PHD

Uterine fibroids are a benign but common condition among women in reproductive age. It is one of the most common reasons for hysterectomy since it often causes bleeding problems sometimes leading to anemia. Several alternative treatment regimens have been investigated that could replace surgery. The antiprogesterone, mifepristone, is one of the most promising drugs that have been tested. In addition to the inhibiting effect on the growth of uterine fibroids antiprogestins have been proposed to have an antiproliferative effect on breast tissue.

The purpose of the present study is to evaluate the effect of mifepristone on the volume of uterine fibroids. The study will also address the effect of mifepristone on the breast tissue

Other purposes of this study include:

* To develop a new non-surgical method for treatment of uterine fibroids
* To study the effect of mifepristone on the size of uterine fibroids
* To evaluate factors regulating fibroid growth by comparison with untreated fibroids and normal myometrium
* To study the effect of mifepristone on the amount of blood loss and pelvic pain in patients with fibroids
* To study the effect of mifepristone on proliferation of breast tissue

The Effect of Mifepristone on Uterine Fibroids and Breast Tissue

The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue

Karolinska Institutet

Kristina Gemzell Danielsson, Professor, MD,PhD

Fibroma

Myoma

Neoplasms, Fibrous Tissue

Jaime Sepulveda, M.D

The purpose of the Fibroid Registry is to provide a comprehensive database that captures patient characteristics, clinical outcomes and pot-treatment quality of life measures for patients treated for uterine fibroids. This database will serve as a platform for future comparative effectiveness and other health services research studies.

The proposed research will be a prospective registry study of patients treated for uterine fibroids at the Fibroid Center located at South Miami Hospitals Center for Women and Infants.

Our objective is to establish the Fibroid Registry:

* To collect and review short, middle and long term clinical outcomes data that will help inform and facilitate the decision making process of clinicians and patients on the safest and most effective treatment for symptomatic uterine myomas, leiomyomas, or fibromas.
* To be able to critically evaluate the quality of procedures being performed and to ultimately establish a gold standard of care based upon patient and clinical outcomes and characteristics.
* To ultimately establish a gold standard of care based upon clinical outcomes and patient characteristics.

South Miami Hospital Fibroid Registry

Such registry will enable us to address a number of research questions, for instance:

* Is uterine artery embolization (UAE) a safe treatment for leiomyomata?
* Is UAE an effective treatment for leiomyomata?
* What is the likelihood of symptom relief?
* How durable is the treatment?
* What is the likelihood that a woman who undergoes UAE and plans subsequent pregnancy will be able to conceive and deliver a subsequent intrauterine pregnancy?
* Are women choosing this procedure content with their selection?
* Are there certain patient subgroups at higher risk or that have an increased likelihood of treatment benefits?

Baptist Health South Florida

embolization

Jean Pierre PELAGE, PUPH

The main goal of this study is to evaluate spontaneous fertility after uterine leiomyomas embolization, in women between 18 and 40 years old.

Uterine artery embolization (UAE) is an effective treatment for leiomyomas, that has been proposed to replace hysterectomy in women who don't want any more pregnancy. Few authors have investigated the results of UAE in women desiring subsequent pregnancy. It might represents an alternative to multiples myomectomies by laparotomy , which results on postoperative fertility remain disappointing. The main goal of this study is to evaluate spontaneous fertility after uterine embolization, in women between 18 and 40 years old. The functional outcome, the efficiency, complications and side-effects of UAE will be also reported especially on the reproduction function. This will be an open prospective, multicentric, non-randomized, interventional study. Within the context of an experimental phase II essay, an optimal Simon plan with 2 stages is required. The current study is the first step. It will include 30 patients treated in the Gynecology departments of Pr MADELENAT and Pr Mathieu CAPUTO (BICHAT Hospital, Paris) and Pr Ville (Poissy Hospital, Poissy). Preliminary results will be reported at 1 year postoperative which correspond to the participation period of 15 months and the total follow-up period will be 2 years. Inclusion criteria will be the women whom multiples myomectomies by laparotomy would be necessary, with symptomatic myoma and an immediate wish of pregnancy. The number of first pregnancies among women who try to be pregnant (conception rate) and among all women (fertility rate) will be calculated. The effects of the embolisation on the genital physiology, the leiomyomas and the ovarian function will be evaluated by questionaries, clinical examination, biology exams (hormones), ultrasound and IRM at 3, 6 and 12 months, and coelioscopy and hysteroscopy at 3 months. The pregnancy progress will be evaluated in a longer study.

Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas

Assistance Publique - Hôpitaux de Paris

Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.

* Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.
* Sample digestion through controlled enzymes.
* Isolated the "Side Population" from leiomyoma cell suspension by Flow cytometry .
* Culture of these cells.
* Morphological and genetic characterization.
* Assessment of pluripotent potential from isolated cells.
* Analysis of the degree of functionality.

Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.

Carlos Simon, MDPhD

The purpose of this study is to identify and characterize the Somatic Stem Cell (SSC) responsible for the formation and growth of leiomyomas using the Side Population method.

The organ of interest in our study is the myometrium, a muscle layer of the uterus located between the perimetry and the endometrium.

The investigators try to identify, locate and characterize the myometrial stem cell population in the uterine fibroids by isolation of "Side Population" by flow cytometry. Once the investigators achieve the purposes to set out, the investigators would try to maintain "in vitro" stem cell population isolated from myometrial fibroids, for further endocrine characterization. Finally, the investigators would try to induce the formation of fibroids in murine models as a first step to demonstrate that the origin of these formations is due to the abnormal proliferation of myometrial adult stem cells. The results of this study will allow the identification of the cell population in the fibroids. The investigators also can being able to compare with the myometrium in order to establish a relationship that helps us to understand more about the pathophysiology of this disease, using these stem cells as targets therapy in the treatment of this myometrium condition.

PHASE 1:SAMPLE COLLECTION Duration: From the first month to 36th month approximately. PHASE 2: CELL PREPARATION PROTOCOL Duration: From the first month to 12th month PHASE 3: ISOLATION OF PUTATIVE SOMATIC STEM CELLS Duration: From the third month (March 2010) to 12th month PHASE 4: CELL CULTURE Duration: From the sixth month to 18th month PHASE 5: ENDOCRINE CHARACTERIZATION Duration:From the 18th month to 36th month Biospecimen Retention Samples With DNA - samples retained, with potential for extraction of DNA from at least one of the types of samples retained (e.g., frozen tissue, whole blood) Biospecimen Description Samples of human leiomyomas obtained from patients with symptomatic uterine fibroids.

Somatic Stem Cells in Leiomyomas?

Identification and Characterization of Putative Leiomyoma Stem Cells.

Assessment of pluripotent potential from isolated cells responsible for the formation and growth of human leiomyomas.

Igenomix

Director of Clinical Research IVI Valencia

Women between the age of 18-55 with fibroids undergoing elective hysterectomy or myomectomy

James Segars, MD

Bhuchitra Singh, MD, MPH, MBA

Rachel Mitchel

The investigators are evaluating the role of senescent cells in uterine fibroids.

Uterine fibroids are prevalent tumors of uterus characterized by excessive fibrotic tissues. Using new cutting-edge computational methods, the investigators have found that small groups of senescent cells in fibroids work in concert with immune cells to produce soluble factors in fibroid tissues to create a feed-forward loop leading to fibrosis. This project seeks to unravel key cell-cell communication networks involving senescent and immune cells in fibroids to develop new treatments for uterine fibroids.

Fibroid, myometrial samples, and peripheral blood sample.

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

Role of Senescent Cells in Uterine Fibroid Pathogenesis

Perform scRNASeq on human fibroids and control myometrium tissue and apply transfer learning algorithm for SnC identification and phenotyping to identify cell-cell communication patterns in fibroids versus control myometrial tissue using Domino to validate computationally predicted senescent cell types. The computationally predicted immune phenotypes will be validated with flow cytometry.

Quantify levels of transcripts and proteins in the fibroid senescence-associated secretory profile (SASP) using ELISA and western blotting techniques

Examine the in-vitro effects of senotherapeutcis using leiomyoma culture models and in mouse models. Measured by inhibition of proliferation, induction of apoptosis, inhibition ECM deposition, decrease in SnCs (senolytics) and senescence-associated secretory profile SASPs (senomorphics).

National Institutes of Health (NIH)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Johns Hopkins University

Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)

Laparoscopically aided myomectomy (LAM) versus LM

Mini laparotomy myomectomy (ML-M) versus UMLT-M

Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)

Wen-Hsun Chang, NB

Ling-Wei Yang, MS

Peng-Hui Wang, M.D., Ph.D.

Uterine leiomyomas (i.e., fibroids, myomas) are the most common gynecologic tumors in women of reproductive age (1). Clearly, the majority of such lesions are asymptomatic (2). Symptoms directly attributable to these benign tumors represent the most common reason for laparotomy in non-pregnant women in the United States (3,4), and also in Taiwan (5). Whereas in decades past, hysterectomy was seen almost as a panacea for uterine leiomyomas, more recently attention has been paid to the development of pharmaceutical agents and less-invasive procedures (6). Frequently, such procedures are designed to retain the uterus (6). Of these, myomectomy may be a choice among the uterine-sparing treatments for symptomatic uterine myoma (7,8).

The surgical mode of access usually employed in myomectomy is traditional exploratory laparotomy or its modification-mini-laparotomy (MLT) (9) or ultra-mini laparotomy (UMLT) (10,11), though recently, laparoscopy (12-14) or a combination of laparoscopy and MLT (9), vaginal surgery (15), and hysteroscopic myomectomy (16-21) have represented valid alternatives. However, myomectomy alone provides varying degrees of symptom control and a high percentage of recurrence, not only for the tumors themselves, but also for the symptoms. For example, one study reported that symptom resolution varied from 84.0% to 100% depending on different items and 21 (19.4%) of 108 patients experienced a recurrence after an average interval of 16 months (range, 1.8-47.4 months) (22). Therefore, an alternative or additional therapy might be required to provide longer durable symptom control and minimize tumor recurrence. One of the strategies is laparoscopic uterine vessel occlusion (LUVO), also known as laparoscopic uterine artery occlusion (LUAO) (23,24).

The rationale for using LUVO in the management of symptomatic myomas is found in the successful experience with uterine-artery embolization (UAE), which was introduced in 1995 as an alternative technique for treating fibroids (25). Since then it has become increasingly accepted as a minimally invasive, uterine-sparing procedure, and studies have reported the relief of excessive menstrual bleeding or pressure in 80-90% of patients (26-32). LUVO provided similar relief of symptoms (89.4% with symptomatic improvement and 21.2% with complete resolution of symptoms) in 2001 in a 7- to 12-month follow-up of 87 patients after LUVO (33).

Since that time there has been rapid growth in the use of this treatment with various modifications, such as simultaneous accompaniment with myomectomy either through laparoscopy or ML, and there has been considerable research into its outcome (22,34-42). However, in our previous data, we found that a combination of LUVO and myomectomy provided definite effectiveness in symptom control for these women with symptomatic uterine myomas (98.1% to 100% symptom resolution depending on various kinds of items), minimized tumor recurrence, and rendered the vast majority of re-interventions unnecessary (22). Myomectomy can be performed by the laparoscopic approach or by ML when patients are undergoing the LUVO procedure. Before 2002, we often used ML to perform myomectomy (22). However, we have shortened the incision to less than 4 cm, creating ultramini-laparotomy (UMLT) to perform myomectomy (10,11,43).

Since many conservative therapies might provide less or more therapeutic effects on the symptom control and disease status, the aim of this prospective study tries to evaluate the therapeutic outcomes of these symptomatic uterine myomas after different kinds of therapies in the coming 5 years at Taipei Veterans General Hospital.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Risk Factors for Uterine Fibroids: A Case Control Study	NCT00339547	Uterine Fibroid...		35 Years - 50 Years	National Institutes of Health Clinical Center (CC)
Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids	NCT01946178	Uterine Fibroid...	Mirabilis High-...	18 Years - 55 Years	Mirabilis Medica, Inc.
Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids	NCT01946178	Uterine Fibroid...	Mirabilis High-...	18 Years - 55 Years	Mirabilis Medica, Inc.
The Effect of Anesthetic Technique on VEGF-C and PGE2	NCT02829333	Uterine Leiomyo...	general anesthe... spinal anesthes...	18 Years - 65 Years	General Hospital of Ningxia Medical University
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue	NCT00579475	Uterine Fibroid...	Mifegyne placebo	18 Years -	Karolinska Institutet
The Effect of Anesthetic Technique on VEGF-C and PGE2	NCT02829333	Uterine Leiomyo...	general anesthe... spinal anesthes...	18 Years - 65 Years	General Hospital of Ningxia Medical University
South Miami Hospital Fibroid Registry	NCT02362009	Uterine Myomas,...		18 Years - 89 Years	Baptist Health South Florida
Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas	NCT00839722	Leiomyomas Fertility	embolization	18 Years - 40 Years	Assistance Publique - Hôpitaux de Paris
Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas	NCT00839722	Leiomyomas Fertility	embolization	18 Years - 40 Years	Assistance Publique - Hôpitaux de Paris
Somatic Stem Cells in Leiomyomas?	NCT01592903	Leiomyomas	Laparoscopic my...	20 Years - 40 Years	Igenomix
Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)	NCT06135870	Fibroid Leiomyoma		18 Years - 55 Years	Johns Hopkins University
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue	NCT00579475	Uterine Fibroid...	Mifegyne placebo	18 Years -	Karolinska Institutet
Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas	NCT00839722	Leiomyomas Fertility	embolization	18 Years - 40 Years	Assistance Publique - Hôpitaux de Paris
The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids	NCT00860002	Uterine Fibroid...		20 Years - 60 Years	Taipei Veterans General Hospital, Taiwan
Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)	NCT06135870	Fibroid Leiomyoma		18 Years - 55 Years	Johns Hopkins University

Spots Global Cancer Trial Database for leiomyomas

Every month we try and update this database with for leiomyomas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for leiomyomas

Every month we try and update this database with for leiomyomas cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for leiomyomas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.